DiscoverTreating TogetherS5 Ep10: Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM
S5 Ep10: Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

S5 Ep10: Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Update: 2024-06-14
Share

Description

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S5 Ep10: Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

S5 Ep10: Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Targeted Oncology